Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (April 2018)
19 slides from Cynata Therapeutics's investor presentation, April 2018
Slide 1: A Next Generation Stem Cell Company
A Next Generation Stem Cell Company Investor Presentation Cynata Therapeutics Limited April 2018
Slide 2: Important Information
Important Information This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necess
Slide 3: Investment overview
Investment overview Unique technology to efficiently mass-produce mesenchymal stem cells (MSCs), 1 a highly promising type of therapeutic stem cell World first clinical trial, with clear early efficacy and safety data received from 1st 2 patient cohort & providing a springboard for further clinical
Slide 4: Corporate overview: A biotech company with a world-first clinical trial
Corporate overview: A biotech company with a world-first clinical trial and leading technology platform Company profile 6 month share price performance § Cynata Therapeutics is an Australian stock exchange listed clinical-stage biotechnology company 1 1400000 0.9 developing disruptive regenerative m
Slide 5: Accelerating towards trial completion
Accelerating towards trial completion May 15 Jan 17 July 17 Jan 17 NEXT... Cymerus platform Strategic Positive pre-clinical Successful DSMB Exercise of license option successfully validated in a partnership and research in GvHD, review and agreement with FUJIFILM GMP manufacturing $4m investment Ast
Slide 6: Why MSCs?
Why MSCs? What are MSCs? CD4+ T Lymphocyte CD8+ T Lymphocyte • Mesenchymal stem cells (MSCs) are highly potent adult stem cells found in ϒδ T Cell bone marrow and certain other tissues. NK Cell What do they do? HLA-G5 • They have the ability to self renew. IDO, iNOS, HO1 PGE2 TGFβ, HGF, PGE2 • They
Slide 7: The Current Challenge
The Current Challenge Excessive culture expansion: “the most egregious divergence between [commercial and academic MSC products] is the scale of product expansion” Cynata’s Cymerus platform solves this challenge…. Source: Galipeau, Cytotherapy, 2013; 15: 2e8 7
Slide 8: Only company in the world with a platform to mass-produce MSCs without multiple donors
Only company in the world with a platform to mass-produce MSCs without multiple donors First generation process has multiple shortcomings Donation taken Purified MSCs then massively Therapeutic MSCs through a complex expanded to provide are administered to Inconsistent product quality surgical proce
Slide 9: Regenerative medicine market growing rapidly and MSCs are a major growth driver
Regenerative medicine market growing rapidly and MSCs are a major growth driver How big is the market for regenerative medicine? “Global regenerative medicine market was worth $18.9 billion in 2016 and will grow to over $53.7 billion by 20211” “Stem cells are the cornerstone of contemporary regenera
Slide 10: Cynata is operating in a highly active market
Cynata is operating in a highly active market Cell therapy is a key category and no longer an evolving market August 2017: US FDA approved Novartis’ product, Kymriah, a T cell (CAR-T) treatment for leukemia August 2017: Gilead to acquire Kite Pharma for US$11.9b. Kite develops similar CAR-T cell pro
Slide 11: Our platform provides a scalable business model, applicable to a broad range of disease targets
Our platform provides a scalable business model, applicable to a broad range of disease targets Vigorous Ongoing External Early monetisation partner revenue collaborations via multiple revenue engagement stream streams Phase: Pre-clinical Phase I, II, III Market What: § Develop Preclinical § Upfront
Slide 12: Indications Currently Being Investigated
Indications Currently Being Investigated External Vigorous partner Further collaborations engagement revenues Pre-clinical Proof of Clinical Deal Product in- Disease target area trials concept secured trial market Key highlights started completed started Graft v Host Disease (GvHD) § Pre-clinical re
Slide 13: Business is focused on progressing the world-first clinical trial of CYP-001 in GvHD
Business is focused on progressing the world- first clinical trial of CYP-001 in GvHD CymerusTM MSCs demonstrated a significant survival benefit in Pre-clinical Completed a pre-clinical rodent model of Graft vs. Host Disease License option agreement secured with Fujifilm, including Completed Partner
Slide 14: GvHD was the optimal first target area for several medical and commercial reasons
GvHD was the optimal first target area for several medical and commercial reasons § MSCs have already shown to be an effective treatment against GvHD In Japan MSCs have been approved for use as a treatment for GvHD § Short trial duration, with expected completion in early 2018 § Successful Cynata tr
Slide 15: GvHD Clinical Trial DSMB Analysis
GvHD Clinical Trial DSMB Analysis • Date Safety Monitoring Board (DSMB) after Day 28 recommended the trial progress to the second cohort of patients (Cohort B) • Cohort B receives a higher dose – two infusions of CYP-001 at 2 million cells per kilogram of bodyweight versus 1 million cells per kilogr
Slide 16: Fujifilm has demonstrated confidence in Cynata's platform through a licensing agreement for GvHD
Fujifilm has demonstrated confidence in Cynata’s platform through a licensing agreement for GvHD is one of the largest License overview: Development and global investors in regenerative medicine commercialisation of Cynata’s MSCs for GvHD § 2014: Fujifilm takes a controlling stake in Japan Strategic
Slide 17: Board and management overview
Board and management overview Dr Paul Wotton Dr Ross Macdonald Dr Stewart Washer Dr John Chiplin Mr Peter Webse Dr Kilian Kelly Chairman Managing Director Non-Executive Non-Executive Non-Executive Director Vice President, Chief Executive Officer Director Director Company Secretary Product Developmen
Slide 18: Investment Summary
Investment Summary Unique technology to efficiently mass-produce mesenchymal stem cells (MSCs), 1 a highly promising type of therapeutic stem cell World first clinical trial in progress with clear early efficacy and safety data received 2 from first patient cohort Cynata’s initial target area is GvH
Slide 19: Thank you for your attention
Thank you for your attention Cynata Therapeutics Limited Contact details: Level 3 ross.macdonald@cynata.com 62 Lygon Street Carlton +61 (0) 412 119343 Victoria 3053 www.cynata.com Australia 19
Cynata Therapeutics — Investor Presentation (April 2018) on 6ix